Boston Scientific has announced that, for the first time in the world, its next generation Promus Premier everolimus-eluting stent has been implanted (at centres in Ireland and The Netherlands) in patients with coronary artery disease.
According to a company press release, the Promus Premier stent system, a new generation coronary stent, was successfully implanted at Trinity Centre for Health Sciences at St. James Hospital, Dublin, Ireland and Erasmus Medical Center, Rotterdam, the Netherlands. The stent is the seventh drug-eluting coronary stent system developed and commercialized by Boston Scientific over the past 10 years.
“I am very pleased to be the first to implant the new Promus Premier stent”, said David Foley from Beaumont Hospital & Mater Private Hospitals, Dublin. “It represents another fine improvement in drug-eluting stent design to improve our ability to treat complex coronary artery disease using minimally invasive techniques.”
The press release reported that the Promus Premier stent system is the only drug-eluting stent to feature a customised stent architecture providing strength without compromising flexibility. It added that Promus Premier also includes an enhanced delivery system featuring a shorter, more flexible tip designed to facilitate precise stent delivery across challenging lesions. Together these features are designed to simplify the procedure for the interventional cardiologist and help improve outcomes for patients living with coronary artery disease.
The Promus Premier stent system is currently offered in a matrix of 47 sizes, ranging in diameter from 2.25mm to 4mm and lengths of 8mm to 38mm on a Monorail catheter platform. This comprehensive offering provides cardiologists and their patients a broad range of options designed to best suit their needs. The Promus Premier stent system is CE marked and not available for sale in the USA or Japan.
